Citations

Showing 10 of 108094 citations.

Potentially Preventable Hospital and Emergency Department Events: Lessons from a Large Innovation Project
Solberg, Leif I. , Ohnsorg, Kris , Magnan, Sanne, Whitebird, Robin R. , Neely, Claire , Brandenfels, Emily, Williams, Mark D. , Dreskin, Mark, Hinnenkamp, Todd, Parker, Emily D. , Ferguson, Robert J. , Ziegenfuss, Jeanette Y.

Mayo Clinic

The Permanente Journal | June 4, 2018 | Volume: 22 | Issue: 3 | Pages: No page available

10.7812/tpp/17-102 | PMID 29911964 Get It

Validation of Noncontact Anterior Cruciate Ligament Tears Produced by a Mechanical Impact Simulator Against the Clinical Presentation of Injury
Bates, Nathaniel A. , Schilaty, Nathan D. , Nagelli, Christopher V. , Krych, Aaron J. , Hewett, Timothy E. , Krych, Aaron J , Schilaty, Nathan D , Bates, Nathaniel A

Mayo Clinic

The American Journal of Sports Medicine | June 4, 2018 | Volume: 46 | Issue: 9 | Pages: 2113-2121

10.1177/0363546518776621 | PMID 29864374 Get It

Background: Anterior cruciate ligament (ACL) injuries are catastrophic events that affect athletic careers and lead to long-term degenerative knee changes. As injuries are believed to occur within the first 50 milliseconds after initial contact during a rapid deceleration task, impact simulators that rapidly deliver impulse loads to cadaveric specimens have been developed. However, no impactor has reproducibly and reliably created ACL injures in a distribution that mimics clinical observation. Purpose: To better understand ACL injury patterns through a cadaveric investigation that applied in vivo–measured external loads to the knee during simulated landings. Study Design: Controlled laboratory study. Methods: A novel mechanical impact simulator reproduced kinetics from in vivo–recorded drop landing tasks on 45 cadaveric knees. Specimens were exposed to a randomized order of variable knee abduction moment, anterior tibial shear, and internal tibial rotation loads before the introduction of an impulse load at the foot. This process was repeated until a hard or soft tissue injury was induced on the joint. Injuries were assessed by an orthopaedic surgeon, and ligament strain was recorded by implanted strain gauges. Results: The mechanical impact simulator induced ACL injuries in 87% of specimens, with medial collateral ligament (MCL) injuries in 31%. ACL tear locations were 71% femoral side, 21% midsubstance, and 9% tibial side. Peak strain before failure for ACL-injured specimens was 15.3% ± 8.7% for the ACL and 5.1% ± 5.6% for the MCL ( P < .001). Conclusion: The ACL injuries induced by the mechanical impact simulator in the present study have provided clinically relevant in vitro representations of in vivo ACL injury patterns as cited in the literature. Additionally, current ligament strains corroborate the literature to support disproportionate loading of the ACL relative to the MCL during athletic tasks. Clinical Relevance: These findings indicate that the mechanical impact simulator is an appropriate model for examining independent mechanical variables, treatment techniques, and preventive interventions during athletic tasks leading up to and including an ACL injury. Accordingly, this system can be utilized to further parse out contributing factors to an ACL injury as well as assess the shortcomings of ACL reconstruction techniques in a dynamic, simulated environment that is better representative of in vivo injury scenarios.
How I treat myelofibrosis after failure of JAK inhibitors
Pardanani, Animesh , Tefferi, Ayalew

Mayo Clinic

Blood | June 4, 2018 | Volume: 132 | Issue: 5 | Pages: 492-500

10.1182/blood-2018-02-785923 | PMID 29866811 Get It

Abstract The introduction of JAK inhibitors, leading to regulatory approval of ruxolitinib, represents a major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in splenomegaly and improved quality of life from symptom improvement. It is a paradox, however, that, despite inhibition of signaling downstream of disease-related driver mutations, JAK inhibitor treatment is not associated with consistent molecular or pathologic responses in MF. Furthermore, there are important limitations to JAK inhibitor therapy including development of dose-limiting cytopenias and/or nonhematological toxicities such as neuropathy or opportunistic infections. Over half of the patients discontinue treatment within 3 years of starting treatment. Although data are sparse, clinical outcome after JAK inhibitor “failure” is likely poor; consequently, it is important to understand patterns of failure to select appropriate salvage treatment(s). An algorithmic approach, particularly one that incorporates cytogenetics/molecular data, is most helpful in selecting stem cell transplant candidates. Treatment of transplant-ineligible patients relies on a problem-based approach that includes use of investigational drugs, or consideration of splenectomy or radiotherapy. Data from early phase ruxolitinib combination studies, despite promising preclinical data, have not shown clear benefit over monotherapy thus far. Development of effective treatment strategies for MF patients failing JAK inhibitors remains a major unmet need.
Teaching NeuroImages: Optic nerve sheath meningioma presenting as gaze-evoked amaurosis
Johnson, Stephen A. , Chen, John J. , Chen, John J , Tobin, W. Oliver , Johnson, Stephen A

Mayo Clinic

Neurology | June 4, 2018 | Volume: 90 | Issue: 23 | Pages: No page available

10.1212/wnl.0000000000005642 | PMID 29866943 Get It

Trials and Frontiers in Carotid Endarterectomy and Stenting
Jones, Douglas W. , Brott, Thomas G. , Schermerhorn, Marc L.

Mayo Clinic

Stroke | June 4, 2018 | Volume: 49 | Issue: 7 | Pages: 1776-1783

10.1161/strokeaha.117.019496 | PMID 29866753 Get It

Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging
Vassilaki, Maria , Cha, Ruth H., Aakre, Jeremiah A. , Therneau, Terry M. , Geda, Yonas E. , Mielke, Michelle M. , Petersen, Ronald C. , Roberts, Rosebud O., Mielke, Michelle M , Geda, Yonas E , Cha, Ruth H., Knopman, David S.

Mayo Clinic

Journal of Alzheimer’s Disease | June 4, 2018 | Volume: 45 | Issue: 4 | Pages: 1237-1245

10.3233/jad-143078 | PMID 25697699 Get It

Background: Etiologic differences in mild cognitive impairment (MCI) subtypes may impact mortality. Objective: To assess the rate of death in MCI overall, and by subtype, in the population-based Mayo Clinic Study of Aging. Methods: Participants aged 70–89 years at enrollment were clinically evaluated at baseline and 15-month intervals to assess diagnoses of MCI and dementia. Mortality in MCI cases versus cognitively normal (CN) individuals was estimated using Cox proportional hazards models. Results: Over a median follow-up of 5.8 years, 331 of 862 (38.4%) MCI cases and 224 of 1,292 (17.3%) cognitively normal participants died. Compared to CN individuals, mortality was elevated in persons with MCI (hazard ratio [HR] = 2.03; 95% CI: 1.61 to 2.55), and was higher for non-amnestic MCI (naMCI; HR = 2.47; 95% CI: 1.80 to 3.39) than for amnestic MCI (aMCI; HR = 1.89; 95% CI: 1.48 to 2.41) after adjusting for confounders. Mortality varied significantly by sex, education, history of heart disease, and engaging in moderate physical exercise (p for interaction <0.05 for all). Mortality rate estimates were highest in MCI cases who were men, did not exercise, had heart disease, and had higher education versus CN without these factors, and for naMCI cases versus aMCI cases without these factors. Conclusions: These findings suggest stronger impact of etiologic factors on naMCI mortality. Prevention of heart disease, exercise vigilance, may reduce MCI mortality and delayed MCI diagnosis in persons with higher education impacts mortality.
Characterizing Topological Patterns in Amnestic Mild Cognitive Impairment by Quantitative Water Diffusivity
Li, Ming , Schwarz, Christopher G. , Zhang, Jiange , Yin, Zhenyu , Qian, Lai, Zhao, Hui , Wang, Kun , Tian, Chuanshuai , Yu, Haiping , Chen, Weibo , Lu, Fangfei, Wu, Wenbo , Yang, Qing , Zhu, Bin , Schwarz, Christopher G , Zhang, Bing , Zhang, Xin , Zhang, Fang , Li, Ming, Xu, Yun

Mayo Clinic

Journal of Alzheimer's Disease | June 4, 2018 | Volume: 43 | Issue: 2 | Pages: 687-697

10.3233/jad-140882 | PMID 25114082 Get It

Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues
O’Bryant, Sid E. , Zhang, Fan , German, Dwight C., Yin, Xiangling, Como, Tori, Reisch, Joan, Huebinger, Ryan M. , Graff‐Radford, Neill R. , Hall, James , O’Suilleabhain, Padraig , Grammas, Paula , Xiao, Guanghua , Edwards, Melissa , Dickson, Dennis W. , Barber, Robert C. , O'Bryant, Sid

Mayo Clinic

Journal of Alzheimer’s Disease | June 4, 2018 | Volume: 42 | Issue: 4 | Pages: 1325-1335

10.3233/jad-141041 | PMID 25024345 Get It

Background: There is a significant need for rapid and cost-effective biomarkers of Alzheimer’s disease (AD) for advancement of clinical practice and therapeutic trials. Objective: The aim of the current study was to cross-validate our previously published serum-based algorithm on an independent assay platform as well as validate across tissues and species. Preliminary analyses were conducted to examine the utility in distinguishing AD from non-AD neurological disease (Parkinson’s disease, PD). Methods: Serum proteins from our previously published algorithm were quantified from 150 AD cases and 150 controls on the Meso Scale Discovery (MSD) platform. Serum samples were analyzed from 49 PD cases and compared to a random sample of 51 AD cases and 62 controls. Support vector machines (SVM) were used to discriminate PD versus AD versus controls. Human and AD mouse model microvessel images were quantified with HAMAMATSU imaging software. Mouse serum biomarkers were assayed via MSD. Results: Analysis of 21 serum proteins from 150 AD cases and 150 controls yielded an algorithm with sensitivity and specificity of 0.90 for correctly classifying AD. This multi-marker approach was then validated across species and tissue. Assay of the top proteins in human and AD mouse model brain microvessels correctly classified 90–100% of the samples. SVM analyses were highly accurate at distinguishing PD versus AD versus controls. Conclusions: This serum-based biomarker panel should be tested in a community-based setting to determine its utility as a first-line screen for AD and non-AD neurological diseases for primary care providers.